6-K 1 a8966r.htm DIRECTOR/PDMR SHAREHOLDING a8966r
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
 
 
For the month of July 2022
 
Commission File Number 001-15170
 
 
GSK plc
(Translation of registrant's name into English)
 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive office)
 
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
 
 
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
 
 
GSK plc (the 'Company')
Transaction notification
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
Ms E Walmsley
 
b)
Position/status
Chief Executive Officer
 
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 1 July 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
 
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
£17.8560
 
462
 
 
£17.8560
 
384
 
 
 
£17.8560
 
575
 
 
 
 
 
d)
Aggregated information
 
 
 
Aggregated volume
Price
 
1,421
£17.8560
 
e)
Date of the transaction
2022-07-05
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
 
Mr I Mackay
b)
Position/status
 
Chief Financial Officer
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 1 July 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
 
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
£17.8560
 
311
 
 
£17.8560
 
266
 
 
£17.8560
 
397
 
 
 
 
 
d)
Aggregated information
 
 
 
Aggregated volume
Price
 
974
£17.8560
 
e)
Date of the transaction
2022-07-05
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
Dr H Barron
 
b)
Position/status
Chief Scientific Officer and President, R&D
 
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
American Depositary Shares ('ADSs')
 
ISIN: US37733W1053
 
b)
Nature of the transaction
Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 1 July 2022 on ADSs held in the Company's Deferred Annual Bonus Plan
 
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
$43.7500
 
262
 
 
$43.7500
 
198
 
 
$43.7500
 
314
 
 
 
 
 
d)
Aggregated information
 
 
 
Aggregated volume
Price
 
 
774
$43.7500
e)
Date of the transaction
 
2022-07-05
f)
Place of the transaction
 
New York Stock Exchange (XNYS)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
Mr R Connor    
 
b)
Position/status
President, Vaccines and Global Health
 
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 1 July 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
 
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
£17.8560
 
145
 
 
 
£17.8560
 
84
 
 
 
£17.8560
 
97
 
 
 
 
 
 
d)
Aggregated information
 
 
 
Aggregated volume
Price
 
 
326
£17.8560
e)
Date of the transaction
 
2022-07-05
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
 
Ms D Conrad
b)
Position/status
 
Chief People Officer
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 1 July 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
 
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
£17.8560
 
60
 
 
£17.8560
 
55
 
 
£17.8560
 
90
 
 
 
 
 
d)
Aggregated information
 
 
 
Aggregated volume
Price
 
205
£17.8560
 
e)
Date of the transaction
2022-07-05
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
Mr J Ford
 
b)
Position/status
SVP and Group General Counsel, Legal and Compliance
 
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 1 July 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
 
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
£17.8560
 
85
 
 
£17.8560
 
67
 
 
£17.8560
 
111
 
 
 
 
 
d)
Aggregated information
 
 
 
Aggregated volume
Price
 
263
£17.8560
 
e)
Date of the transaction
2022-07-05
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
Ms S Jackson
 
b)
Position/status
SVP, Global Communications and CEO Office
 
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
 
GSK plc
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 1 July 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
 
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
£17.8560
 
36
 
 
£17.8560  
     
33
 
 
£17.8560
 
51
 
 
 
 
 
d)
Aggregated information
 
 
 
Aggregated volume
Price
 
 
120
£17.8560
e)
Date of the transaction
 
2022-07-05
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
 
Mr B McNamara
b)
Position/status
 
CEO, GSK Consumer Healthcare
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
American Depositary Shares ('ADSs')
 
ISIN: US37733W1053
 
b)
Nature of the transaction
Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 1 July 2022 on ADSs held in the Company's Deferred Annual Bonus Plan
 
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
$43.7500
48
 
 
 
$43.7500
 
60
 
 
 
$43.7500
 
33
 
 
 
 
 
 
 
 
 
 
d)
Aggregated information
 
 
 
Aggregated volume
Price
 
 
141
$43.7500
e)
Date of the transaction
 
2022-07-05
f)
Place of the transaction
 
New York Stock Exchange (XNYS)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
 
Mr L Miels
b)
Position/status
 
Chief Commercial Officer
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 1 July 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
 
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
£17.8560
139
 
 
 
£17.8560
104
 
 
 
£17.8560
189
 
 
 
 
 
 
d)
Aggregated information
 
 
 
Aggregated volume
Price
 
 
432
£17.8560
e)
Date of the transaction
 
2022-07-05
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
 
Ms S Ramakrishnan
b)
Position/status
Chief Digital and Technology Officer
 
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
American Depositary Shares ('ADSs')
 
ISIN: US37733W1053
 
b)
Nature of the transaction
Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 1 July 2022 on ADSs held in the Company's Deferred Annual Bonus Plan
 
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
$43.7500
19
 
 
 
 
 
 
d)
Aggregated information
 
N/A (single transaction)
 
Aggregated volume
Price
 
 
e)
Date of the transaction
2022-07-05
 
f)
Place of the transaction
 
New York Stock Exchange (XNYS)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
 
Mr D Redfern
b)
Position/status
 
Chief Strategy Officer
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)
Nature of the transaction
 
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 1 July 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
£17.8560
102
 
 
 
£17.8560
 
81
 
 
 
£17.8560
 
125
 
 
 
 
 
 
d)
Aggregated information
 
 
 
Aggregated volume
Price
 
 
308
£17.8560
e)
Date of the transaction
 
2022-07-05
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
 
Mr R Simard
b)
Position/status
 
President, Pharmaceuticals Supply Chain
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 1 July 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
 
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
£17.8560
72
 
 
 
£17.8560
61
 
 
 
£17.8560
113
 
 
 
 
 
 
d)
Aggregated information
 
 
 
Aggregated volume
Price
 
 
246
£17.8560
e)
Date of the transaction
 
2022-07-05
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
 
Mr P Thomson
b)
Position/status
 
President, Global Affairs
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 1 July 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
 
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
£17.8560
59
 
 
 
£17.8560
47
 
 
 
£17.8560
79
 
 
 
 
 
 
d)
Aggregated information
 
 
 
Aggregated volume
Price
 
185
£17.8560
e)
Date of the transaction
 
2022-07-05
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
Ms D Waterhouse
 
b)
Position/status
CEO, ViiV Healthcare
 
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 1 July 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
 
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
£17.8560
 
98
 
 
£17.8560
 
83
 
 
 
 
 
d)
Aggregated information
 
 
 
Aggregated volume
Price
 
 
181
£17.8560
e)
Date of the transaction
2022-07-05
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
 
SIGNATURES
 
 
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 
GSK plc
 
(Registrant)
 
 
Date: July 08,2022
 
 
 
 
By:/s/ VICTORIA WHYTE
--------------------------
 
 
 
Victoria Whyte
 
Authorised Signatory for and on
 
behalf of GSK plc